Pomegra
Lead
Shares of Cooper Companies (COO) fell approximately 18% on Wednesday, making it the session's steepest single-name decline outside of ServiceTitan, after the San Ramon, California-based medical device maker missed Q3 revenue estimates, surprised investors by completing its strategic review without a sale of CooperSurgical, and issued Q4 earnings guidance roughly 11% below what Wall Street had forecast. The combined blows - a revenue shortfall, a deal that markets had priced in a sale never arriving, and a fourth consecutive guidance cut - triggered broad-based selling across the medical device sector.
- COO posted Q3 revenue of $1.07 billion, missing the $1.10 billion consensus, and cut its full-year revenue forecast to $4.23-$4.25 billion from $4.29-$4.32 billion.
- After a nine-month strategic review, the board voted to retain CooperSurgical rather than pursue a sale - markets had priced in a sale, and the reversal erased anticipated deal premium.
- Q4 EPS guidance midpoint of $1.07 trailed the $1.20 analyst consensus by 11%, marking the company's fourth guidance reduction in two years.
What Drove Cooper Companies' 18% Drop?
The selloff reflected three simultaneous disappointments hitting in a single earnings release. Q3 revenue came in at $1.07 billion, short of the $1.10 billion consensus, with CooperVision contact lenses growing 6% to $718.4 million and CooperSurgical contributing $341.9 million, up 4%. Overall year-over-year revenue growth amounted to just 1%.
Management attributed the revenue shortfall partly to an intentional drawdown of U.S. contact lens distribution channel inventory during the strategic review period - a process that is expected to continue weighing on Q4 results. While Q3 adjusted earnings per share of $1.15 edged past the $1.12 consensus, the headline revenue miss and forward guidance reset overshadowed any beat on the bottom line.
Why Did the CooperSurgical Decision Disappoint Markets?
The board's unanimous decision to retain CooperSurgical effectively eliminated a deal premium that investors had built into the stock over nine months of review. Markets had priced in a sale following the December 2025 announcement of the strategic process, and the absence of a transaction forced a repricing of COO shares to reflect standalone fundamentals - now clouded by near-term earnings headwinds.
The board stated that offers received during the process did not adequately reflect CooperSurgical's value, citing temporary factors that suppressed bids, including a new competitive entrant into the non-hormonal IUD market and the financial impact of a fertility-related litigation settlement. While those factors may resolve over time, the market's immediate reaction priced in neither recovery nor a future transaction.
What Does the Guidance Imply About Near-Term Growth?
The Q4 EPS guidance range of $1.05 to $1.09 - a $1.07 midpoint against a $1.20 consensus - implies continued margin compression and little sequential revenue recovery. The full-year revenue forecast reduction to $4.23-$4.25 billion, from a prior range of $4.29-$4.32 billion, signals that the inventory normalization and CooperSurgical headwinds are not short-lived. For a company that has now cut guidance four times in two years, the pattern has become a credibility concern as much as an operational one.
Strategic Context
CooperSurgical's retention shifts the strategic narrative from potential portfolio simplification back to organic execution. The unit contributes approximately one-third of consolidated revenue and has faced specific market pressures that are difficult to isolate from broader portfolio performance. Retaining the business keeps optionality intact for a future sale at better valuation, but removes any near-term catalyst tied to deal activity.The company's full strategic pivot - absorbing inventory, stabilizing CooperSurgical margins, and rebuilding earnings trajectory - now falls to President and CEO Albert G. White and his leadership team without the financial flexibility that a divested unit would have provided.
Market Reaction
COO ranked as the session's worst-performing major single-name decliner outside of ServiceTitan. Multiple analysts moved to neutral ratings and reduced price targets to the $59-$61 range from prior targets in the mid-$80s, citing the guidance reset and the strategic review conclusion as catalysts for de-rating. Trading volumes were significantly elevated relative to recent averages. Healthcare sector ETFs experienced modest sympathy pressure as investors reassessed medical device earnings trajectories more broadly.
Outlook
Cooper Companies faces a compressed timeline to restore guidance credibility following four consecutive cuts. The Q4 period will reveal whether the U.S. CooperVision inventory drawdown resolves as management has indicated, and whether CooperSurgical can stabilize margins under new competitive pressure. Without a deal catalyst, the investment thesis reverts to organic earnings growth - a harder case to make after Wednesday's update. The stock will likely remain range-bound until either Q4 results confirm the company's recovery narrative or a new strategic action reintroduces deal optionality.
Mentioned tickers: COO
